Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Severe Persistent Allergic Asthma (INNOVATE)
NCT00046748Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2001
- Primary completion
- Apr 2004
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of omalizumab in allergic asthma, sponsored by Novartis. Started Dec 2001; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00046748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046748.